Introduction In an attempt to benefit from the cost-savings associated with use of generic medicines, in June 2013 Ireland introduced generic substitution and reference pricing for the first time. However, perceptions of Irish patients towards generic medicines have not been published previously. Therefore, the objective of this study was to assess how generic medicines were perceived amongst patients in the time leading up to the enactment of the new legislation. Methodology A total of 42 patients were recruited from general practices affiliated with the Graduate Entry Medical School at the University of Limerick and from community pharmacies. Interviews were semi-structured and included quantitative assessments of opinions using 15 structured questions and a five-point Likert scale response system. Interview transcripts were coded and thematically analysed using NVivo (version 9), for qualitative data. Quantitative data were analysed using SPSS (version 20). Results Nearly one-third (31 %) of patients had no knowledge of generic medicines and 39 % of those exhibited confusion between the words 'generic' and 'genetic'. Almost one-quarter (24 %) held the view that generics were of poorer quality than originators, while 18 % expressed the opinion that generics do not work as well as originator products. Approximately one-third (30 %) of patients believed that generics were manufactured to a poorer quality, with 29 % holding the view that generics are less expensive due to being of inferior quality. Nearly 90 % of patients stated they would take a generic medicine if it were prescribed by their GP; however, 24 % of patients stated a preference, if offered a choice, for the originator medication. Additionally, a majority of patients (86 %) were in favour of reference pricing and generic substitution. Of the patients interviewed, 50 % stated that a leaflet, or similar, with appropriate, understandable, and accessible information regarding generic medicines would be of use to them. Conclusion This is the first study of patients' attitudes towards generic medicines in Ireland. Conducted in the time period leading up to the implementation of legislation promoting the use of generic medicines, it highlights variable knowledge about generic medicines among this key stakeholder group. Although patients are supportive of their more widespread use, concerns regarding safety, clinical effectiveness, and manufacturing quality of generic medicines were identified.
18 % expressed the opinion that generics do not work as well as originator products. Approximately one-third (30 %) of patients believed that generics were manufactured to a poorer quality, with 29 % holding the view that generics are less expensive due to being of inferior quality. Nearly 90 % of patients stated they would take a generic medicine if it were prescribed by their GP; however, 24 % of patients stated a preference, if offered a choice, for the originator medication. Additionally, a majority of patients (86 %) were in favour of reference pricing and generic substitution. Of the patients interviewed, 50 % stated that a leaflet, or similar, with appropriate, understandable, and accessible information regarding generic medicines would be of use to them. Conclusion This is the first study of patients' attitudes towards generic medicines in Ireland. Conducted in the time period leading up to the implementation of legislation promoting the use of generic medicines, it highlights variable knowledge about generic medicines among this key stakeholder group. Although patients are supportive of their more widespread use, concerns regarding safety, clinical effectiveness, and manufacturing quality of generic medicines were identified.
Key Points for Decision Makers
• Up to June 2013, Ireland did not have a system of generic substitution or reference pricing, as is the norm in many other countries. As such, pharmacists in Ireland were legally obliged to dispense medicines exactly as written on the prescription and could not dispense a lower cost, equivalent generic alternative if the proprietary medicine had been prescribed by name. Hence, the state incurred the full cost of such medicines for those on state-funded medicines schemes.
• Spending on pharmaceuticals in Ireland is high, the highest in the EU per capita in 2010 [1] , for example, the annual cost of medicines under the state-funded drugs schemes increased from €564 million in 2000 to €1,961 million in 2009 [2] . Thus, the Irish government has recognized that increasing usage of generic medicines has the potential to make significant savings to the exchequer. As such, new legislation introducing generic substitution and reference pricing in Ireland was signed into law in June 2013.
• No studies have been published in the past that investigated perceptions of generic medicines in the Irish patient cohort.
• Patients are not fully aware of what generic medicines are and express doubts as to their efficacy and quality. Despite these misgivings, patients exhibit a high degree of trust in medical professionals and would take a generic drug, if prescribed by a trusted physician, despite their own lack of confidence in generics.
Introduction
In June 2013, the Irish Government signed a new Act into law (the Health [Pricing and Supply of Medical Goods] Act 2013) [1] . Despite generic substitution 1 and reference pricing 2 being used in other European countries [2] (for example, generic substitution was introduced in Sweden in 2002 [3] , in Finland in 2003 [4] , and has long been an integral part of the British National Health System, amongst others [5] ), the situation in Ireland, prior to this legislation, required that the pharmacist supply only the medicine indicated by the prescribing physician, even if there was a less expensive, generic version available (unless the prescription was written generically, that is, using the non-proprietary name of the medicine). The implication of this legislation is that generic substitution and reference pricing will be implemented for the first time in this market. A practical aspect of this implementation, targeting reduction of Ireland's considerable drug expenditure costs (in 2010, per capita spending on pharmaceuticals in Ireland was the highest in the EU, 34 % above the average [6] ), is that Irish patients are now more likely than ever before to receive a generic medicine. Consequently, patients' perceptions of generic medicines will be an important facet for successful implementation of the new Act. Despite this, to the authors' knowledge, as of July 2013, no research on Irish patients' views had been published. Hence, there is a gap in knowledge related to Irish patients' perceptions of generic medicines. Furthermore, only 18 reports (five of which were not in English) have been published, in the last 10 years, on the topic of patient perceptions of generic medicines [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , indicating that this is a relatively under-explored area internationally.
A 1997 report prepared for the then Irish Minister for Health, describing a previous attempt by the Irish government to increase usage of generic drugs, contains some historical perspective on Irish patient attitudes to generic medicines [25] . Specifically, the report stated that over half of the patients surveyed indicated a willingness to consume less expensive versions of medicines and that 83 % were happy with the outcome of medication changes (to a generic drug) [25] . However, in the intervening time period, usage of generic medicines has not significantly increased (from approximately 22 % in 1997), and Ireland's usage of generic medicines has remained amongst the lowest in Europe, with observed prescribing rates in 2012 as low as 19 % [2, 26, 27] .
With Ireland on the cusp of a major modification in healthcare practices (that is, the introduction of generic substitution and reference pricing, for the first time), there are many potential hurdles to be overcome [28] . To determine what challenges might arise as a consequence of patient opinions, the objective of this study was to assess how generic medicines were perceived amongst this critical stakeholder group, in the time leading up to the enactment of the new legislation.
Methodology

Recruitment and Survey Interviews
Approval of the design and conducting of this study was granted by the Ethics Committee of the Irish College of General Practitioners (ICGP). 1 Generic substitution is the substitution of an equivalent, nonbranded, medicine for a prescribed branded (usually, proprietary) medication, which generally happens at pharmacy level. 2 A reference price is the price that will be reimbursed by the State for a medicine (in a group of designated interchangeable medicines). Where a patient chooses not to receive a reference priced medicine, the patient must pay any difference between the reference price and the price of the chosen medication. This additional payment is known as a co-payment.
Patients were recruited from practices of general practitioners (GPs) affiliated with the University of Limerick's Graduate Entry Medical School and from community pharmacies. Patients from both urban and rural locations (throughout the South/South-East of Ireland and therefore broadly reflective of Ireland's socio-demographic profile) were approached in person and invited to participate in the study. All patients present in the GP surgery waiting room/ community pharmacy were verbally invited to participate. If a willingness to participate was expressed, the study was explained to them verbally, a written explanation (patient participation leaflet) was provided, and they were then entered into the study. As per the granted ethical approval, agreement to participate in the study was taken as patient consent (no signed consent forms were required). Patients waiting to see their GP were interviewed on the day (in a private consultation room). Those recruited from community pharmacies were generally interviewed at a later date, either face-to-face or via telephone (as arranged when consent to participate was given).
All interviews were performed with consenting patients between November 2012 and April 2013. (The primary author performed the interviews. The interviewer had formal training on design of questionnaires and completion of interviews and is also a professional lead auditor of quality management systems with over 15 years of experience). Interviews were conducted until data saturation had been achieved. The study instrument was informed by a recently published review of the usage of generic medicines and how policy changes to promote the use of generic medicines may affect healthcare provision [2] . Interviews, which were recorded (with each interviewee's permission), were primarily semi-structured and based on a series of questions to which open, or qualitative, answers could be given (Table 1) , and further questioning or discussion could be completed, if required, to more fully elucidate participant views. Additional quantitative assessment of opinions was completed by use of a series of 15 structured, closed questions to which participants could select from pre-defined answers (Table 2) . In this instance, a five-point Likert scale [29] was used with a single response allowed for each question, selected from 'Strongly Agree, Agree, Neutral, Disagree, and Strongly Disagree'. This mixedmethods approach was adopted in order to maximize data gathering using both quantitative scales and provision of opportunity for patients to volunteer free commentary on the topic. Furthermore, participants were offered the opportunity to freely express any additional opinions or views at the end of each interview.
Analysis of Data
Interviews were transcribed verbatim and imported into NVivo (version 9) for analysis. Transcripts were coded for themes relating to interviewee opinions, perceptions, and behaviors, including any other emerging themes, and the results were analysed using Nvivo. To facilitate visualization and understanding of the numbers of participants holding the perceptions/behaviors that were coded into specific themes, these were expressed as a percentage of the total number of participants.
Analysis of quantitative data was completed using SPSS (version 20).
Participants
A total of 42 patients were interviewed. Patient group demographics are described in Table 3 .
Results
Familiarity of Patients with Generic Medicines
Nearly one-third, 31 % (13/42), of patients interviewed stated that they had no knowledge of generics, or ''no idea what they were.'' Of those, 39 % (5/13) of patients confused the word 'generic' with 'genetic' when asked to explain what they believed a generic medicine to be. This misunderstanding became obvious as some patients answered positively that they had heard of generics, but could not provide an explanation as to what a generic medicine was, often speaking about genetic illnesses, for example: Additionally, 31 % (13/42) of patients had no knowledge as to whether they had ever taken a generic medicine in the past.
Opinions Regarding Quality, Safety, and Efficacy of Generic Medicines
Patients' opinions showed a certain lack of confidence in generics, with 24 % holding the view that generics were of a poorer quality than originators and in the region of onefifth (18 %) to one-quarter (26 %) of patients (Table 2: statements 6 and 4, respectively) being of the view that generics do not work as well as originator products: 
15 If I were ill, I would prefer to take an originator medicine rather than a generic medicine, even if it is more expensive 9 24 26 68 3 8
Of 42 patients interviewed, four declined to answer these questions as they felt that they did not have enough knowledge or information to provide answers. Therefore, n = 38 patients for this segment a Strongly agree/agree b Strongly disagree/disagree c Neutral/no opinion Well I'd imagine the branded medicine would be more tested and that you'd probably get a better result from it. Female, aged 50-64 years. Personally I think that the generic medicine is maybe not as potent as the original medicine, for various different reasons, they're manufactured more cheaply so I think possibly that the products that go into them are sourced from a cheaper source, so I think maybe that they're not as good as the original. Female, aged 40-49 years.
Nearly one-fifth (18 %) of patients were unsure as to whether generics were as safe as originators and 29 % of patients explicitly stated that they believed generics were manufactured to a poorer quality than originator medications. Up to 42 % of patients held the view that generic medicines are cheaper because they are of inferior quality to originators (Table 2: statement 13) (This is an amalgamation of the SA/A and N responses, the phrase 'up to' indicates the maximum percentage of respondents who could hold this view).
…[the generic is not as good] because it's cheaper to produce and maybe, that the same quality of ingredients that's in it, they're not the same quality as the [originator]… Female, aged 50-64 years. I don't know what actually goes into medicines or tablets but if they're not the good brand, there must be cheaper stuff that they're putting in or that they're not putting in most of the ingredients or other stuff. Female, aged 30-39 years.
Preferences for Branded Medication
Patients exhibited a high level of trust in their GPs as, despite the opinions expressed above, 90 % (34/38) of patients stated that they would be happy to take a generic medicine if prescribed by their GP. In contrast, 24 % (9/38) of patients expressed a preference for the originator medication, if offered a choice; 19 % (8/42) of patients stated an explicit belief that the branded medication was better than a generic formulation.
… I would be inclined to think [the generic] would be inferior to the branded one. Female, aged 50-64 years.
Views Regarding Cost of Generic Medicines
Patients who provided an opinion as to why generic medicines may be less expensive than originator medicines stated licensing expiration and introduction of competition as the most common factor: 29 % (12/42). Other opinions expressed were because, with a generic, the consumer was no longer ''paying for the name'' 17 % (7/42); that generics come from a ''cheaper country'' 7 % (3/42); that ''cheaper'' (implying a lower standard than the originator) ingredients go into them 12 % (5/42); and because packaging was not as good 5 % (2/42).
Opinions of New Legislation
A majority, 86 % (36/42), of patients expressed opinions in favor of generic substitution; 29 % (12/42) additionally expressed the opinion that they should be informed of any substitution and that a substitution should not take place without their consent. A majority of patients (86 % [36/ 42] ) were also in favor of reference pricing, stating that it made sense and was necessary for cost-savings for the country (the reference price is the reimbursement price of a medicine, set by the government, which it will reimburse to pharmacies for patients on publically funded drug schemes who have been dispensed that medicine).
I actually strongly agree with [reference pricing] because people, on the medical card system, don't understand how expensive medication is and take it for granted. So I think that if you want a particular brand name… if you insist, the onus should be on you to pay the difference. Female, aged 30-39 years.
While a majority (71 % [30/42] ) of patients were of the opinion that co-payment was reasonable (the co-payment is a payment that can be made, over and above the reference price, by a patient on a publically [i.e. State] funded drug scheme who wishes to receive a medication that is more expensive than the reference priced medicine), they also stated that they would probably never make a co-payment (21 % [9/42]), that is, they would accept the reference priced medicine. Moreover, 17 % (7/42) of patients stated that there should be some way for patients not to have to make the co-payment where there were genuine medical reasons for them needing to take the originator (which is allowed for in the Act, but of which they were unaware; possibly indicating that, while in favor of legislation in principle, they are generally ill informed as to the detail and, therefore, the full impact of the new system being implemented).
Information Available to Patients
None of the patients interviewed reported ever having been given any specific information by their GP or pharmacist that explained to them what a generic medicine was, and how a generic might differ from the originator brand.
The only time I've ever got [information] was when the pharmacist actually offered me the generic version and the only explanation I got was ''I'm giving you the generic version because it's cheaper''. That was the only information. Male, aged 50-64 years.
A small number (10 % [4/42]) of patients referred to a need for education to be provided regarding generic medicines. One-half of patients interviewed (21/42) stated that a leaflet or similar with such information would be useful to them, provided that it was written in an easy to understand manner, with no technical wording or jargon used.
I think there's been a genuine lack of information about generic medicine, across the board and its been very much, I think, government policy not to inform the general population about generic medicine and about the option of having generic medicines and its only now that the country is broke that it's forced to look at cheaper alternatives. Male, aged 40-49 years.
Concerns About Variation in Appearance of Generic Medicines
Safety concerns were expressed by 10 % (4/42) of patients in relation to the varying appearance of generics and the impact that this can have on patients. Several anecdotes were provided regarding the confusion that can be caused-particularly in relation to elderly family members-when the appearance of their medications changed each time they refilled a prescription. Indeed, one patient told a story of her mother needing to be hospitalized after confusing two different medications, due to the appearance of the tablets being so similar, when they had, in the past, been different colours.
I know myself that my mother is getting generic medicines now instead of the original brand … but she does get a bit confused as to why she's getting this instead of something else … she's used to taking a particular tablet and then suddenly she's being given something else and they're not the same, [older people] don't realise that it's the same thing because it's called something else. Female, aged 40-49 years.
Influence of the Pharmaceutical Industry
A small number of patients (7 % [3/42]) expressed the opinion that they felt that doctors were being influenced by the manufacturers of medicines to prescribe brand name drugs in favour of less expensive alternatives.
I think [branded medicines] are being forced on us by doctors and especially when you see … the brand all around doctors surgeries as well … I think that doctors are nearly encouraged by pharmaceutical companies, I don't know if there's any monetary benefit to it but I think they're encouraged to give us branded drugs. Female, aged 18-29 years.
Discussion
There have been numerous publications focused on generic medicines, their introduction, subsequent use, and aspects of efficacy or otherwise [2] . However, there has been relatively limited literature regarding the attitudes of patients towards these products in the last decade. While studies have originated from Norway (patients attitudes to generic substitution) [30] , Finland (preferences of patients for generic and branded over-the-counter [OTC] pain medicines) [13] , Portugal (patient perceptions of underuse of generics and their attitudes towards generic substitution) [20] , South Africa (consumer perceptions of generic drug quality compared with actual drug quality) [19, 31] , New Zealand (patients' perceptions, knowledge, and attitudes regarding generic medicines and investigation of patients' attitudes towards generic substitution of oral antipsychotics) [9, 22] , Iraq (consumers' knowledge relating to generic medicines) [24] , and the USA (patient knowledge of, and attitudes relating to, formulation switching of antiepileptic drugs) [32] , amongst others, the perceptions of Irish patients with regard to generic medicines have not been published previously. Moreover, only four other interviewbased studies of the opinions of patients regarding generic medicines could be found (PubMed search, July 2013) and the number of participants in this study is comparable to those studies from Iraq [24] , Norway [12] , and the USA [33, 34] , which interviewed 14, 83, 30, and 50 participants, respectively. While this study redresses that gap in the literature, an initial interesting observation was that while about twothirds (69 %) of Irish patients had a correct understanding of what a generic medicine is, patient confusion existed regarding the words 'generic' and 'genetic'. This may result in overestimation of the general public's understanding of generic medicines in surveys that do not delve beyond an initial awareness.
As in other studies from the United Arab Emirates [7] , Norway [11, 30] , Finland [13] , and France [15] , a significant proportion of the patient cohort expressed mistrust in generic medications and a preference for branded medication. However, patients demonstrated a high level of trust in their GP, and had faith in what is prescribed for them by their GP, even when the patients themselves held the opinion that generics are inferior to originator medications. This also mirrors results reported elsewhere regarding patient trust in prescribing by their physicians [20] .
Well if the doctor would prescribe the medicine and say it's as good as the branded I would take it. With respect to information about generic medicines and their availability to patients, patients expressed the opinion that any leaflets/information, etc. needed to be written in such a way that they could be easily understood and without the use of jargon or scientific/technical terms. Considering that, despite healthcare professionals' best efforts, educational interventions with patients can often be unsuccessful [35] ; ensuring that such information is readable and understandable by the general public is essential. Indeed, our group has recently published a novel tool, based on optimized quality of information and reading ability, for development of websites providing healthcare information that could be utilized in the provision of such information to patients [36] .
Analogous to results from New Zealand [9] and Finland [37] , a substantial number of patients were seen to have negative attitudes towards generics and, therefore, there remains considerable scope to educate the patient group, thereby improving their confidence in, and hence acceptance of, generic medicines. This has the potential to be pivotal not only for the success of the new legislation, in an Irish context, but also for a continued improvement in usage of generics worldwide. Educational interventions are recognised as being a vital requirement to ensure patient understanding of generic medications [19, 20, 24, 31, 38] (e.g., such products often have a different visual presentation to the originator, knowledge of which could be valuable in preventing issues of confusion and medication errors associated with a switch to a generic formulation). Additionally, patients might benefit from improved understanding that generic medicines are not identical in content to the originator; indeed, it has been shown that differences in excipients can result in significant issues for some patients [32, 39, 40] .
A possible limitation of this study is that participants' opinions were gathered in differing interview settings, that is, some participants were interviewed face-to-face in a GP surgery, and others were interviewed over the telephone. Given that location of interviews may have an impact on participants [41] this might have influenced the data gathered in this study. However, review and comparison of the themes emerging from participants interviewed in different settings did not show any substantial difference in the opinions, perceptions, and behaviors expressed between participants interviewed in different settings. Furthermore, while the authors acknowledge that quantification of qualitative data is sometimes contentious, we chose to adopt this approach in order to best provide easy visualization of results and offer a more comprehensive insight into the patient perspective. The strengths of such an approach have been discussed by Schönfelder in 2011 [42] .
Future work in this area, as suggested by Timonen et al. [43] in their work on similar changes in Finland, would be to evaluate the changes made several years after its introduction, from a number of perspectives. In particular, it would be interesting to examine the usage of 'Do Not Substitute' (DNS) prescriptions to determine if patient preference for branded medication has transferred to a demand for DNS prescriptions from physicians and, indeed, if physicians yield to this demand. Given that the intent of the new Act is to reduce the drugs bill for the Irish state, over-use of DNS prescriptions has the potential to negate some of the financial benefits expected to accrue.
Conclusions
It is clear from this study that areas for improvement of perceptions of generic medicines still remain. In an era when usage of generic medicines is an ever-increasing and necessary part of cost control in healthcare provision, elucidation of the root causes of persisting negative opinions about generic medicines is important to determining the actions to be taken to mitigate them. However, determining such root causes must be done with care, as high-level surveys that do not investigate the deeper understanding of study participants may overestimate the level of understanding of, or familiarity with, generic medications (or any other topic). Provision of information/ education to patients, in a jargon-free, easy-to-understand manner, which explains the differences as well as the similarities, including the equivalency of generic medicines, may be key to improving patient opinions and negating the mistrust that the patient cohort exhibits.
